PECAM1 and spindle cell hemangioma: Flow cytometry analyses of CD31 expression indicated that the differentiation efficiency declined to 6–10% with Losma treatment in all three stages (Fig. 2a) and with SCH (Fig. 2b) treatment in stage 1.